The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells
about
Update: the status of clinical trials with kinase inhibitors in thyroid cancerIn-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.Molecular pathogenesis and mechanisms of thyroid cancerAkt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer.Disruption of mutated BRAF signaling modulates thyroid cancer phenotypeNew therapies for dedifferentiated papillary thyroid cancerMathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival RatesFOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinomaEvolving approaches to patients with advanced differentiated thyroid cancerBiomarkers of response to Akt inhibitor MK-2206 in breast cancerMK-2206, an AKT inhibitor, promotes caspase-independent cell death and inhibits leiomyoma growth.Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma.Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells.Recent Advances on Small-Molecule Survivin Inhibitors.Genetics and epigenetics of sporadic thyroid cancer.Selective use of vandetanib in the treatment of thyroid cancer.PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro.Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines.Thyroid cancer cell lines: Critical models to study thyroid cancer biology and new therapeutic targets.PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells.Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells.MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
P2860
Q33570056-90776636-85CA-455E-9B1B-EA8D41107181Q33601377-597A3BB5-F075-4FB4-B1A3-074141A99B8DQ34329018-C69ADFB0-03FE-4ADE-9E3A-8577C4A6852FQ35104869-C2DDFE9C-EA08-4F8C-B6BF-818DFD9A175EQ35132767-4FEA3F81-4D1F-489A-8BEE-44FA974BC934Q35381593-46332F7B-D754-4148-AF81-C9D2D465526EQ36634818-64809416-691B-471D-8102-6A5E0DCE7D47Q36799818-523F1064-2201-46B1-AD6E-5B25128E675AQ36864736-406C492F-927C-4AD9-95EC-0C51031D22BAQ37168778-A02FCC10-B1D4-422C-A140-7CF30394AA36Q37240206-D79532D0-8113-499F-BA64-D9B4D924AED1Q37625891-2391D3F9-38F1-4F7A-8F09-01289EBD2180Q37635839-2FF54128-8111-4EED-ADB9-6F3F56EEDF53Q37689286-C32E6B11-08FC-40BC-B91C-A195198F3AA7Q38128097-769CDA0C-7779-4DE9-B6DE-D0FE323E6964Q38546474-0F4885F9-68BC-43EB-8D87-666E2CF32658Q38644584-49B10068-18D9-40D0-A9FD-6C52B28D5A32Q39245623-5B76CFC5-32C3-4D37-AE0D-57CB521AC2B2Q39246432-C95F2D17-71A5-4C8D-BD3F-F7418C192894Q39326839-6AFDDBD8-A78D-4B2B-8EF5-31445DB47167Q41628138-40391DC1-FE5E-4867-9502-3D31E455B108Q42370484-F2519F1E-17BA-4268-A417-9B98D1597E82Q48273491-9435E50C-1CF7-400F-ABA7-7B70EC09289DQ54111658-D39F7C95-C93F-401F-B359-63EE46AFC1F2
P2860
The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The Akt inhibitor MK2206 syner ...... bition of thyroid cancer cells
@ast
The Akt inhibitor MK2206 syner ...... bition of thyroid cancer cells
@en
type
label
The Akt inhibitor MK2206 syner ...... bition of thyroid cancer cells
@ast
The Akt inhibitor MK2206 syner ...... bition of thyroid cancer cells
@en
prefLabel
The Akt inhibitor MK2206 syner ...... bition of thyroid cancer cells
@ast
The Akt inhibitor MK2206 syner ...... bition of thyroid cancer cells
@en
P2860
P356
P1476
The Akt inhibitor MK2206 syner ...... bition of thyroid cancer cells
@en
P2093
Mingzhao Xing
Ruixin Liu
P2860
P304
P356
10.1210/JC.2011-1054
P407
P50
P577
2011-11-16T00:00:00Z